Recruiting

Phase 1

B7-H3 CAR T Cell TherapyAutologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease

Sponsor:

National Cancer Institute (NCI)

Code:

NCT07509034

Conditions

Extensive-Stage Small Cell Lung Cancer

Extrapulmonary Neuroendocrine Carcinoma

Recurrent or Refractory

Solid Tumors

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Autologous B7-H3 CAR T

Cyclophosphamide

Fludarabine

Study Details

Brief summary:

Background:

Small cell lung cancer (SCLC) is the deadliest form of lung cancer. Extrapulmonary neuroendocrine cancer (EPNEC) is a similar type of cancer that develops anywhere other than the lungs. EPNEC is also deadly. B7-H3 is a protein often found in SCLC and EPNEC tumor cells. Researchers can modify a person s own T cells, or immune cells, to target B7-H3. When these modified T cells are returned to the body-a treatment called B7-H3 chimeric antigen receptor (CAR) T cell therapy-they may help kill cancer cells.

Objective:

To test B7-H3 CAR T cell therapy in people with SCLC or EPNEC.

Eligibility:

People aged 18 years and older with SCLC or EPNEC that either did not respond or returned after treatment.

Design:

Participants will be screened. They will have blood tests and tests of their heart function. They will have imaging scans.

Participants will undergo apheresis: Blood will be taken from the body through a needle. The blood will pass through a machine that separates out the T cells. The remaining blood will be returned to the body through a different needle. The collected T cells will be altered to make them attack cells with B7-H3.

Participants will be in the hospital for at least 15 days. They will receive chemotherapy drugs to prepare their body for the treatment. These drugs will be given through a tube attached to a needle inserted into a vein.

The modified T cells will be infused through a vein. Participants will remain in the hospital until they are well enough to go home.

Follow-up visits will continue for 15 years....

Conditions

Extensive-Stage Small Cell Lung Cancer

Extrapulmonary Neuroendocrine Carcinoma

Recurrent or Refractory

Solid Tumors

Study ID

NCT07509034

Start date

Sep 28, 2026

Status verified date

Sep 18, 2026

Completion date

Jan 30, 2031

Anticipated

Primary completion date

Jan 30, 2030

Anticipated

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

INCLUSION CRITERIA:
Age >=18 years old.
Histologically confirmed small cell lung cancer (SCLC) or extrapulmonary neuroendocrine cancers (EP-NEC) that has recurred following or is refractory to first-line therapy. Note: small cell cancers of non-lung primary sites are also eligible.
Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-2.
Pulse oximetry >= 90% on room air.
Aspartate Transferase (AST) < 3 X institutional upper limit of normal (ULN). Note: in case of liver metastases <= 5 X ULN is acceptable.
Alanine Aminotransferase (ALT) < 3 X institutional ULN. Note: in case of liver metastases <= 5 X ULN is acceptable.
Total bilirubin <=2 X institutional ULN.
Creatinine <=1.5 X institutional ULN OR creatinine clearance (CrCl) >= 50 mL/min/1.73m\^2 (calculated by the Chronic Kidney Disease Epidemiology Collaboration \[CKD-EPI\] formula or calculated eGFR provided by a laboratory).
Absolute Neutrophil Count (ANC) >= 750/mcL.
Platelet count >= 75,000/mcL.
An absolute lymphocyte count (ALC) >=300/mcL and CD3+ cell count >=150/mcL.
Normal cardiac ejection fraction as defined by >= 45% by echocardiogram (ECHO) at screening.
At least 1 measurable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 that has not been previously irradiated.
Recovered from acute toxic effects of all prior cancer therapy to Grade <2 per Common Terminology Criteria for Adverse Events (CTCAE) v.6.0 at least one week before apheresis excluding the parameters for ANC and ALC mentioned above.
The following criteria must be met prior to apheresis:

Chemotherapy and biologic/targeted agents:

>=14 days since the last dose of standard myelosuppressive chemotherapy.
>= 7 days since the completion of biologic agent, targeted agent, or tyrosine kinase inhibitor therapy.
>= 3 weeks or 5 half-lives (whichever is shorter) since prior therapy with a monoclonal antibody.
Radiotherapy:

>= 1 week since the last radiotherapy session.
No washout period required for palliative radiation to non-target lesions.
>= 3 weeks since hepatic radiation, chemoembolization, and/or radiofrequency ablation.
Steroids and immunosuppressive therapy:

Corticosteroids: >= 2 weeks since the therapeutic doses (> 0.5 mg/kg/day prednisone or equivalent). Note: Inhaled or topical steroids are not exclusionary.
Physiologic replacement doses (up to 5 mg/day prednisone equivalent) are allowed and can be adjusted based on participant's BMI if warranted.
>= 2 weeks since the other immunosuppressive medication (e.g., calcineurin inhibitors, methotrexate, rapamycin, thalidomide, etc.).
Anti-PD-1 and any investigational therapies:

>= 2 weeks since Anti-PD-1 monoclonal antibody therapy.
>= 2 weeks or 5 half-lives of the investigational product (whichever is shorter) since any investigational treatment or clinical trial participation.
Other criteria:

72 hours since small molecule tyrosine kinase inhibitors (e.g., EGFR inhibitors), PARP inhibitors, or KRAS G12C inhibitors.
Individuals of childbearing potential (IOCBP) must agree to use highly effective contraception (hormonal, intrauterine device \[IUD\], abstinence, surgical sterilization) at the study entry and up to 12 months after the last dose of combined chemotherapy.

Note: IOCBP is defined as any individual who has experienced menarche and who has not undergone successful surgical sterilization or who is not postmenopausal.

Individuals able to father a child must agree to use an effective method of contraception (barrier, surgical sterilization, abstinence) at the study entry and up to 7 months after the last dose of study drugs. We also will recommend individuals able to father a child with partners of childbearing potential ask partners to be on highly effective birth control (hormonal, IUD, surgical sterilization). Individuals able to father a child must not freeze or donate sperm within the same period.
Nursing participants must be willing to discontinue nursing from study treatment initiation through 6 months after the last dose of the study drug(s).
Ability of the participant to understand and the willingness to sign a written informed consent document.

EXCLUSION CRITERIA:

History of anaphylactic reactions attributed to anti-B7-H3 antibodies or compounds of similar chemical or biologic composition to autologous B7-H3 CAR T cells, cyclophosphamide, fludarabine, or other agents used in this study.
Infection exposure with the human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) as defined below:

Positive serology for HIV.
Active HBV infection as demonstrated by test for hepatitis B surface antigen (HBsAg).
Positive serology for HCV.
Prior gene therapy using an integrating vector (except for autologous B7-H3 CAR T cells retreatment).
History of any previous allogeneic hematopoietic stem cell transplant.
Presence of fungal, bacterial, viral, or other infection is permitted if responding to active treatment.
Central Nervous System (CNS) disorder such as cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or autoimmune disease with CNS involvement that may impair the ability to evaluate neurotoxicity.
Pregnancy confirmed with beta-human chorionic gonadotropin (beta-HCG) serum or urine pregnancy test in IOCBP at screening.
Uncontrolled intercurrent illness or medical condition(s) evaluated by medical history, physical exam, electrocardiogram (ECG) or situations that would unacceptably increase risk for the participant or impair the ability to evaluate the endpoints of the study.

Study Design

Enrollment

40 participants

Anticipated

Allocation

Non randomized

Intervention Model

Sequential

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Dose Escalation

Escalating doses of autologous B7-H3 CAR T cells.

experimental: Dose Expansion

Maximum tolerated dose (MTD) or maximum administered dose (MAD) of autologous B7-H3 CAR T cells.

Interventions

Autologous B7-H3 CAR T

For both dose escalation and expansion phases, B7-H3 CAR T cell infusion will be performed following lymphodepleting therapy. Up to 2 years post the initial infusion, participants will be offered the option for an additional infusion of B7-H3 CAR T cells at the same dose level as the initial dose, with or without LD if eligible.

Cyclophosphamide

For both dose escalation and expansion phases, FDA approved lymphodepleting agents, cyclophosphamide and fludarabine will be used on this study prior to the administration of T cells.

Fludarabine

For both dose escalation and expansion phases, FDA approved lymphodepleting agents, cyclophosphamide and fludarabine will be used on this study prior to the administration of T cells.

Primary outcome measure

Determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) of autologous B7-H3 CAR T cells [ Time Frame: Dose Limiting Toxicity (DLT) period (day 0 through day 28) ]
Determine disease control rate (DCR) [ Time Frame: Until disease progression or 15 years, whichever occurs first ]

Central Contacts and Locations

Central contacts

Danielle F Pinkiert, R.N.

(240) 858-7566 danielle.pinkiert@nih.gov

Nicholas P Tschernia, M.D.

(240) 506-3532 nick.tschernia@nih.gov

Locations

National Institutes of Health Clinical Center

Recruiting

Bethesda, Maryland, United States, 20892

Contacts

National Cancer Institute Referral Office

888-624-1937 ncimo_referrals@mail.nih.gov

More Information

Sponsor

National Cancer Institute (NCI)

Last update posted

Sep 23, 2026

Last verified

Sep 18, 2026

Keywords

B7-H3
CAR-T
Phase I
Immunotherapy

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-24. This information was provided to ClinicalTrials.gov by National Cancer Institute (NCI) on 2026-09-23. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.